CTIC - CTI BioPharma Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
47.33M
Enterprise Value 3
2.31M
Trailing P/E
N/A
Forward P/E 1
-0.83
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
2.98
Price/Book (mrq)
1.16
Enterprise Value/Revenue 3
0.14
Enterprise Value/EBITDA 6
-0.07

Trading Information

Stock Price History

Beta (3Y Monthly) 2.18
52-Week Change 3-61.65%
S&P500 52-Week Change 38.19%
52 Week High 32.0400
52 Week Low 30.6000
50-Day Moving Average 30.7963
200-Day Moving Average 30.8373

Share Statistics

Avg Vol (3 month) 3130.2k
Avg Vol (10 day) 352.23k
Shares Outstanding 557.98M
Float 35.71M
% Held by Insiders 10.76%
% Held by Institutions 161.04%
Shares Short (Sep 30, 2019) 4312.72k
Short Ratio (Sep 30, 2019) 42.42
Short % of Float (Sep 30, 2019) 40.64%
Short % of Shares Outstanding (Sep 30, 2019) 40.54%
Shares Short (prior month Aug 30, 2019) 4279.24k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 210/1
Last Split Date 3Jan 3, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -225.01%
Operating Margin (ttm)-218.00%

Management Effectiveness

Return on Assets (ttm)-25.64%
Return on Equity (ttm)-72.52%

Income Statement

Revenue (ttm)15.89M
Revenue Per Share (ttm)0.27
Quarterly Revenue Growth (yoy)-32.10%
Gross Profit (ttm)25.41M
EBITDA -34.07M
Net Income Avi to Common (ttm)-35.75M
Diluted EPS (ttm)-0.6160
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)53.66M
Total Cash Per Share (mrq)0.93
Total Debt (mrq)17.5M
Total Debt/Equity (mrq)50.02
Current Ratio (mrq)3.15
Book Value Per Share (mrq)0.70

Cash Flow Statement

Operating Cash Flow (ttm)-35.46M
Levered Free Cash Flow (ttm)-23.84M